Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}
• Allele Name: targeted mutation 4, Fanxin Long
• Allele ID: MGI:5613577
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm4(Wnt7b)Flng/Gt(ROSA)26Sor^+ Tg(Runx2-rtTA*M2)#Flng/0 Tg(tetO-cre)1Jaw/0	involves: 129 * C57BL/6	MGI:5613585
cn2	Gt(ROSA)26Sor^tm4(Wnt7b)Flng/Gt(ROSA)26Sor^+ Rptor^tm1Rueg/Rptor^tm1Rueg Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0	involves: 129S1/Sv * 129X1/SvJ * CD-1	MGI:5613582
cn3	Gt(ROSA)26Sor^tm4(Wnt7b)Flng/Gt(ROSA)26Sor^+ Rptor^tm1Rueg/Rptor^+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0	involves: 129S1/Sv * 129X1/SvJ * CD-1	MGI:5613583
cn4	Gt(ROSA)26Sor^tm4(Wnt7b)Flng/Gt(ROSA)26Sor^+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0	involves: CD-1	MGI:5613581
cn5	Gt(ROSA)26Sor^tm4(Wnt7b)Flng/Gt(ROSA)26Sor^+ Tg(Col1a1-cre)1Ack/0	involves: FVB/N	MGI:5613584

Genotype
MGI:5613585

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/Gt(ROSA)26Sor⁺; Tg(Runx2-rtTA*M2)#Flng/0; Tg(tetO-cre)1Jaw/0
• Genetic Background: involves: 129 * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

skeleton

abnormal bone structure ( J:208766 )

decreased osteoclast cell number ( J:208766 )

• after doxycycline treatment

increased bone mineral density ( J:208766 )

• in the long bones after doxycycline treatment

increased trabecular bone volume ( J:208766 )

• proximal tibial trabecular bone volume/total volume is increased 6.6 fold at 2 months of age after doxycycline treatment

increased osteoblast cell number ( J:208766 )

• markedly increased after doxycycline treatment

increased trabecular bone mass ( J:208766 )

• marked increase in the trabecular bone mass in both primary and secondary ossification centers

increased bone ossification ( J:208766 )

• increased bone formation after doxycycline treatment

immune system

decreased osteoclast cell number ( J:208766 )

• after doxycycline treatment

hematopoietic system

decreased osteoclast cell number ( J:208766 )

• after doxycycline treatment

Genotype
MGI:5613582

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/Gt(ROSA)26Sor⁺; Rptor^tm1Rueg/Rptor^tm1Rueg; Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * CD-1

skeleton

abnormal bone structure ( J:208766 )

• when cre expression is suppressed by doxycycline treatment until 1 month of age then stopped, 3 weeks later bone mass is reduced compared to mutant mice with one wild-type Rptor allele

abnormal bone marrow cavity morphology ( J:208766 )

• when cre expression is suppressed by doxycycline treatment until 1 month of age then stopped, 3 weeks later bone marrow cavity is larger than in mutant mice with one wild-type Rptor allele but still smaller than in controls not over expressing Wnt7b

increased osteoblast cell number ( J:208766 )

• when cre expression is suppressed by doxycycline treatment until 1 month of age then stopped, 3 weeks later osteoblast number is increased

• however, unlike in mice with one wild-type Rptor osteoblast hyperactivity is reduced

Genotype
MGI:5613583

cn3

• Allelic Composition: Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/Gt(ROSA)26Sor⁺; Rptor^tm1Rueg/Rptor⁺; Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * CD-1

skeleton

abnormal bone marrow cavity morphology ( J:208766 )

• when cre expression is suppressed by doxycycline treatment until 1 month of age the marrow cavity is decreased

increased bone mass ( J:208766 )

• when cre expression is suppressed by doxycycline treatment until 1 month of age mice show very high bone mass 3 weeks after stopping doxycycline treatment

Genotype
MGI:5613581

cn4

• Allelic Composition: Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/Gt(ROSA)26Sor⁺; Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
• Genetic Background: involves: CD-1

skeleton

abnormal long bone morphology ( J:208766 )

• at E16.5 display a much thicker bone collar and no bone marrow

decreased length of long bones ( J:208766 )

abnormal bone structure ( J:208766 )

abnormal bone marrow cavity morphology ( J:208766 )

• at E16.5 the marrow region is occupied by cells that appear to be preosteoblasts and no marrow cavity is formed

• at E18.5 the marrow region is populated by mature osteoblasts

increased bone mineral density ( J:208766 )

• profoundly dense bones throughout the body at 2 months of age

increased osteoblast cell number ( J:208766 )

• at E18.5 the marrow region is populated by mature osteoblasts

increased bone mass ( J:208766 )

• at E18.5 and 2 months of age

• when cre expression is suppressed by doxycycline treatment until 1 month of age mice show a profound high bone mass phenotype at 2 months of age

delayed chondrocyte differentiation ( J:208766 )

• slight delay in chondrocyte maturation at E14.5

Genotype
MGI:5613584

cn5

• Allelic Composition: Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/Gt(ROSA)26Sor⁺; Tg(Col1a1-cre)1Ack/0
• Genetic Background: involves: FVB/N

skeleton

abnormal tibia morphology ( J:208766 )

• proximal tibial trabecular bone volume/total volume is increased 13.7 fold and 5.1 fold at 2 months and 6 months of age, respectively

• by 9 months of age bone mass of the proximal tibial trabecular area is 30% less than controls

abnormal bone structure ( J:208766 )

decreased osteoclast cell number ( J:208766 )

• osteoclast number per bone surface and percentage of bone resorption surface are reduced at 2 months of age

abnormal bone marrow cavity morphology ( J:208766 )

• absence of a marrow space in the long bones due to complete ossification

increased bone mineral density ( J:208766 )

• profoundly dense bones in both males and females throughout the body at 2 months of age

• increased density persists at 6 months of age but is partially resolved at 9 months of age

decreased trabecular bone volume ( J:208766 )

• by 9 months of age bone mass of the proximal tibial trabecular area is 30% less than controls

• however, bone mass remains increased in the distal tibia and femur at 9 months of age

increased trabecular bone volume ( J:208766 )

• proximal tibial trabecular bone volume/total volume is increased 13.7 fold and 5.1 fold at 2 months and 6 months of age, respectively

increased osteoblast cell number ( J:208766 )

• excessive osteoblasts in the presumptive marrow cavity at E18.5

• increased osteoblast number normalized to bone surface at 2 months of age

• however, the density of osteocytes is similar to controls

increased bone mass ( J:208766 )

• excessive bone occupies both primary and secondary ossification centers but the growth plate remains largely normal

• increased bone mass is seen at E18.5 and at 2 and 6 months of age

increased bone ossification ( J:208766 )

• mineral apposition rate, the percentage of mineralizing surface, and bone formation rate are all increased in the humerus

increased bone resorption ( J:208766 )

• increase in the serum levels of C-terminal telopeptide of type I collagen (a degradation product of type I collagen released upon bone resorption) at 1 and 9 months of age but not at 2 months of age

homeostasis/metabolism

increased circulating osteocalcin level ( J:208766 )

• increased at 1 and 2 months of age

increased circulating type I collagen C-terminal telopeptide level ( J:208766 )

• increase in the serum levels of C-terminal telopeptide of type I collagen (a degradation product of type I collagen released upon bone resorption) at 1 and 9 months of age but not at 2 months of age

hematopoietic system

enlarged spleen ( J:208766 )

• consistent with extramedullary hematopoiesis

increased spleen weight ( J:208766 )

decreased osteoclast cell number ( J:208766 )

• osteoclast number per bone surface and percentage of bone resorption surface are reduced at 2 months of age

immune system

enlarged spleen ( J:208766 )

• consistent with extramedullary hematopoiesis

increased spleen weight ( J:208766 )

decreased osteoclast cell number ( J:208766 )

• osteoclast number per bone surface and percentage of bone resorption surface are reduced at 2 months of age

limbs/digits/tail

abnormal tibia morphology ( J:208766 )

• proximal tibial trabecular bone volume/total volume is increased 13.7 fold and 5.1 fold at 2 months and 6 months of age, respectively

• by 9 months of age bone mass of the proximal tibial trabecular area is 30% less than controls

growth/size/body

enlarged spleen ( J:208766 )

• consistent with extramedullary hematopoiesis

increased spleen weight ( J:208766 )